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OBJECTIVES The primary objective was to evaluate the usefulness of transesophageal echocardiography
(TEE)-guided cardioversion to prevent thromboembolic complications in patients with atrial
fibrillation (AF) and effective anticoagulation (International Normalized Ratio of 2 or 3) at
least three weeks before cardioversion.
BACKGROUND Transesophageal echocardiography has been proposed as a method of screening patients for
left atrial thrombi before direct-current cardioversion of AF. The usefulness of TEE as a
screening tool has always been evaluated in patients without long-term anticoagulation before
cardioversion.
METHODS This prospective, single-center, observational study, performed on an intention-to-cardiovert
basis, comprised 1,076 consecutive, unselected patients with AF. The initial two years were
designed to be the control phase, during which the conventional approach was used. After
that, cardioversion guided by TEE was performed in consecutive patients.
RESULTS The prevalence of left atrial thrombi was 7.7% in patients with persistent AF and effective
anticoagulation. During the first four weeks after electrical cardioversion, six thromboembolic
complications were observed in patients in whom the TEE-guided approach was employed
(6 [0.8%] of 719 patients), compared with three thromboembolic complications in patients in
whom the conventional approach was used (3 [0.8%] of 357 patients). None of the patients
in whom electrical cardioversion was not performed experienced an embolic event.
CONCLUSIONS There were no differences in the rate of embolic events between the two treatment groups. In
patients with AF and effective anticoagulation, TEE-guided electrical cardioversion does not
reduce the embolic risk. However, TEE revealed left atrial thrombi in 7.7% of patients with
AF and effective anticoagulation, before direct-current cardioversion. (J Am Coll Cardiol
2002;39:1436–42) © 2002 by the American College of Cardiology Foundation
Transesophageal echocardiography (TEE) has been dem-
onstrated to be more sensitive than transthoracic echocar-
diography for the detection of left atrial thrombi and
spontaneous echo contrast, a putative marker of thrombo-
embolic risk (1–5).
Clinical data are emerging in support of the usefulness
and safety of the TEE-guided approach to cardioversion
(1–11). However, all previous studies have evaluated the
usefulness in patients with no anticoagulation or only
short-term anticoagulation before direct-current cardiover-
sion (6–11).
The primary objective of this study was to evaluate the
usefulness of TEE-guided cardioversion to prevent throm-
boembolic complications in patients with atrial fibrillation
(AF) and effective anticoagulation (International Normal-
ized Ratio [INR] of 2 to 3) at least three weeks before
direct-current cardioversion in clinical practice.
METHODS
Patient selection. Patients who were candidates for elec-
trical cardioversion of AF were eligible for enrollment in the
study. Patients were excluded if 1) anticoagulation was
ineffective (INR 2); or 2) they had hemodynamically
unstable AF that had to be cardioverted. All patients gave
written, informed consent.
Study design. This prospective, single-center, observa-
tional study was designed on an intention-to-cardiovert
basis. During the first two years (control phase), patients
were treated according to the recommendations of the
American College of Chest Physicians (12): three weeks of
warfarin therapy before cardioversion, followed by four
weeks of warfarin therapy, and a follow-up examination at
the end of four weeks. Effective anticoagulation was
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achieved if the patient had an INR between 2 and 3 at least
three weeks before electrical cardioversion.
After the initial two years, TEE-guided cardioversion
was performed in consecutive patients. If thrombi were
detected, cardioversion was postponed. In patients with
moderate to severe spontaneous echo contrast, the decision
to cardiovert was left to the treating physician. The antico-
agulation regimen was the same as the regimen in the
conventional (control) group.
Patients with ineffective anticoagulation. Ineffective an-
ticoagulation was established if warfarin was given but the
INR was 2, if no anticoagulation was performed because
of AF for 48 h or if there were contraindications against
anticoagulation. Patients with ineffective anticoagulation
were excluded; however, follow-up was performed. The
reasons for performing direct-current cardioversion in pa-
tients with ineffective anticoagulation were AF for 48 h,
hemodynamically unstable AF or contraindications against
anticoagulation. After cardioversion, a combination of war-
farin therapy and intravenous heparin therapy was given to
maintain adequate anticoagulation after cardioversion in
patients without contraindications against anticoagulation.
Echocardiography before cardioversion. Conventional
transthoracic echocardiography (TTE) was performed in
both study groups before cardioversion (13–16). During the
TEE study, special attention was paid to assess the presence
or absence of left atrial thrombi and spontaneous echo
contrast (13–16).
A thrombus was considered to be present if a mass
detected in the appendage or body of the atrium appeared to
be distinct from the underlying endocardium, was not
caused by pectinate muscles and was detected in more than
one imaging plane (17,18).
Spontaneous echo contrast was defined as dynamic
smoke-like echoes within the atrial cavity, with the charac-
teristic swirling motion that could not be eliminated by
changes in gain settings. The degree of spontaneous echo
contrast was characterized independently as absent, mild,
moderate or severe (17,19).
The severity of spontaneous echo contrast was graded
according to the following criteria: “mild” was defined as
minimal echogenicity located in the left atrial appendage or
sparsely distributed in the main cavity of the left atrium,
which was possible to detect only transiently during the
cardiac cycle, but imperceptible at operating gain settings
for two-dimensional echocardiographic analysis. “Moder-
ate” was defined as a dense, swirling pattern in the left atrial
appendage, generally associated with somewhat lesser inten-
sity in the main cavity, which may fluctuate in intensity, but
detectable constantly throughout the cardiac cycle. “Severe”
was defined as an intense echo density and a very slow
swirling pattern in the left atrial appendage, usually with a
similar density in the main cavity (18–21). The delay
between these echocardiographic studies and the scheduled
cardioversion was 3 h.
Clinical outcomes. Determination of a thromboembolic
event was based on the clinical findings and supported by
radiologic studies. The clinical safety outcomes were clini-
cally apparent ischemic stroke, transient ischemic attack,
systemic embolization, death related to cardioversion and
episodes of bleeding. Other outcome variables were the
prevalence of thrombi, the number of patients without
thrombi who had cardioversion and the immediate rhythm
after cardioversion. These outcomes were assessed for four
weeks after cardioversion. In patients in whom no cardio-
version was performed because of spontaneous conversion to
sinus rhythm or contraindications against cardioversion,
these variables were assessed for four weeks after the date of
the planned cardioversion.
Statistical analysis. Clinical echocardiographic and out-
come data are reported as the mean value  SD. For
dichotomous outcome variables, percentages are given. The
Mann-Whitney U test was used for the comparison of
continuous variables between two groups. For the compar-
ison of dichotomous outcomes, the chi-square test or Fisher
exact test for small numbers was performed, and crude odds
ratios with 95% confidence intervals were computed. All
statistical tests were two-tailed, with statistical significance
set at p  0.05.
RESULTS
Patient group. Between January 1994 and July 2000, 1,269
consecutive patients were registered. Anticoagulation was
ineffective in 193 patients. Therefore, 1,076 patients with
AF and effective anticoagulation were entered into the final
analysis. The TTE group (conventional therapy group)
consisted of 357 patients, and the TEE group consisted of
719 patients. Patients in the TEE group were older and
more often had a history of hypertension, a history of stroke
or transient ischemic attack, structural heart disease, an
ejection fraction 40% and a larger left atrial diameter. In
addition, patients in the TEE group more often had
episodes lasting longer than two days, compared with
patients in the conventional treatment group. Regarding
anticoagulant therapy, no differences between the two
groups were detected (Table 1).
Conventional therapy group. CARDIOVERSION SUCCESS.
Electrical cardioversion was performed in 355 (99%) of 357
patients. Cardioversion was successful in 278 (78%) of 355
patients (Table 1).
In two patients, no electrical cardioversion was performed
Abbreviations and Acronyms
ACUTE  Assessment of Cardioversion Using
Transesophageal Echocardiography study
AF  atrial fibrillation
INR  International Normalized Ratio
LV  left ventricular
TEE  transesophageal echocardiography
TTE  transthoracic echocardiography
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(1 patient had spontaneous restoration of sinus rhythm, and
in 1 patient, the treating physician decided against cardio-
version) (Fig. 1A).
OUTCOME. In the conventional therapy group, a total of
three thromboembolic events occurred in the first four
weeks after cardioversion (0.8%). In the initial 48 h after
electrical cardioversion, no thromboembolic complications
occurred in these patients. All three patients experienced a
thromboembolic stroke. No bleeding complications were
observed in the conventional therapy group (Table 2).
Transesophageal echocardiography group. TRANS-
ESOPHAGEAL ECHOCARDIOGRAPHY BEFORE CARDIOVER-
SION. A thrombus was found in the left atrium in 55 (7.7%)
of 719 patients. In 374 (52%) of the 719 patients, TEE
revealed spontaneous echo contrast. The grade of sponta-
neous echo contrast was mild in 63%, moderate in 27% and
severe in 10% of patients (Table 1).
CARDIOVERSION SUCCESS. In 586 patients (82%), electrical
cardioversion was performed. It was successful in 505 (86%)
of the 586 patients (Table 1). Cardioversion was not
performed in 133 patients (18.5%) in the TEE-guided
group: 25 (3%) had spontaneous restoration of sinus
rhythm; 104 patients did not have cardioversion because
TEE revealed left atrial thrombi or moderate to severe
spontaneous echo contrast; 3 patients had no cardioversion
because the treating physician decided against it; and 1
patient declined cardioversion (Fig. 1A).
OUTCOME. In the TEE-guided group, a total of six throm-
boembolic events (Table 2) occurred in the first four weeks
after cardioversion (0.8%). Two patients had a transient
ischemic attack in the first 48 h after cardioversion. After
48 h and during the first four weeks after cardioversion,
another four thromboembolic events occurred in the TEE-
guided group. Two patients had an ischemic stroke, one
patient had a transient ischemic attack and one patient had
a peripheral embolism. None of the patients with throm-
boembolic complications after cardioversion had evidence of
left atrial thrombi before cardioversion. In all patients with
a thrombus, the INR was increased to 3 to 3.5. After four
weeks, resolution of thrombus was observed in 55% of
patients.
During four weeks of follow-up, two bleeding complica-
tions occurred. One patient had a hemorrhagic stroke three
weeks after the planned electrical cardioversion. This pa-
tient had not been cardioverted because of a thrombus in the
orifice of the left atrial appendage (INR 3.1). One patient
had lung bleeding during the first four weeks of follow-up
(INR 4.7) (Table 2). None of the 133 patients without
electrical cardioversion experienced a thromboembolic com-
plication.
Table 1. Patient Characteristics: Comparison Between Patients Studied by Transesophageal
Versus Transthoracic Echocardiography
Total Group
(N  1,076)
TTE Group
(n  357)
TEE Group
(n  719) p Value
Age in years (n) 63  10 (1,076) 63  10 (357) 64  10 (719) 0.003
Male 74% (797/1,076) 78% (278/357) 72% (519/719) 0.05
Hypertension 54% (583/1,070) 50% (176/351) 57% (407/719) 0.05
Diabetes 12% (124/1,069) 9% (33/351) 13% (91/718) NS
History of TIA/stroke 10% (110/1,076) 8% (27/357) 12% (83/719) 0.05
Duration of AF 2 days 85% (662/777) 76% (170/225) 89% (492/552) 0.0001
Duration of AF in median days (n) 28 (777) 21 (225) 28 (552) 0.001
Organic heart disease 57% (608/1,069) 51% (180/350) 60% (428/719) 0.01
CAD 40% (242/608) 33% (60/180) 43% (182/428) 0.035
DCM 15% (92/608) 12% (22/180) 16% (70/428) NS
HHD 42% (254/608) 43% (77/180) 41% (177/428) NS
VHD 27% (165/608) 27% (49/180) 27% (116/428) NS
Others 5% (29/608) 8% (14/180) 4% (15/428) 0.02
EF 40% 15% (152/1,044) 7% (24/326) 18% (128/178) 0.0005
LA diameter in mm (n) 46  6 (1,007) 45  6 (306) 46  6 (701) 0.0005
Spontaneous echo contrast 52% (374/719) ND 52% (374/719) —
Mild 63% (237/374) — 63% (237/374) —
Moderate 27% (100/374) — 27% (100/374) —
Severe 10% (37/374) — 10% (37/374) —
LA thrombus 7.7% (55/719) ND 7.7% (55/719) —
INR (n) 2.6  0.7 (1,076) 2.5  0.6 (357) 2.6  0.7 (711) NS
CV performed 87% (941/1,076) 99% (355/357) 82% (586/719) 0.0005
CV not performed 13% (135/1,076) 1% (2/357) 18.5% (133/719) 0.0005
Spontaneous CV 2% (26/1,076) 0.3% (1/357) 3% (25/719) 0.01
Successful CV 83% (783/941) 78% (278/355) 86% (505/586) 0.01
Data are presented as the mean value  SD or percentage (n/N) of patients).
AF  atrial fibrillation; CAD  coronary artery disease; CV  electrical cardioversion; DCM  dilated cardiomyopathy;
EF  ejection fraction; HHD  hypertensive heart disease; INR  International Normalized Ratio; ND  not done; NS 
not significant; LA  left atrial; TIA  transient ischemic attack; TEE  transesophageal echocardiography; TTE 
transthoracic echocardiography; VHD  valvular heart disease.
1438 Seidl et al. JACC Vol. 39, No. 9, 2002
Cardioversion of Atrial Fibrillation May 1, 2002:1436–42
Figure 1. Distribution of patients by (A) effective anticoagulation and (B) ineffective anticoagulation. AC  anticoagulation; CV  cardioversion; pt(s) 
patient(s); TEE  transesophageal echocardiography.
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Comparison of patients with and without a thromboem-
bolic event. Although the number of patients with embolic
complications was too small to permit meaningful statistical
comparisons between the groups, it is notable that patients
with embolic complications did not have a longer duration
of AF (32 vs. 28 days, p  NS), nor a larger left atrium
(46  4 vs. 46  6 mm, p  NS), nor a greater prevalence
of spontaneous echo contrast (33% vs. 52%, pNS), mitral
valve disease (p  NS) or left ventricular (LV) dysfunction
(0% vs. 15%, p  NS), compared with patients without
thromboembolic complications.
Patients with ineffective anticoagulation. In 193 patients,
anticoagulant therapy was ineffective at the time of the
intended cardioversion. Patients with ineffective anticoagu-
lation were younger (59 12 vs. 63 10 years, p 0.001),
less often had a history of hypertension (46% vs. 54%, p 
0.032), more often had AF that lasted 48 h (61% vs. 15%,
p  0.001), less often had organic heart disease (49% vs.
57%, p  0.036), less often had impaired LV function
(ejection fraction 40%; 9% vs. 15%, p  0.035) and more
often had a smaller left atrium (44  6 vs. 46  6 mm, p 
0.001), compared with patients with effective anticoagulation.
Transesophageal echocardiography was performed in 126
patients. A thrombus was found in 10 patients (7.9%). No
differences were observed when comparing patients who had
a thrombus detected with effective anticoagulation to pa-
tients who had a thrombus detected with ineffective anti-
coagulation.
Outcomes. In 150 patients (78%), electrical cardioversion
was performed. Cardioversion was successful in 128 (85%)
of 150 patients (Fig. 1B). In 2 (1.3%) of 150 patients, a
transient ischemic attack occurred in the first four weeks
after cardioversion. In both patients, TEE was performed
before cardioversion. None of the patients had evidence of a
left atrial thrombus before cardioversion. However, TEE
revealed mild to moderate spontaneous echo contrast. None
of the 43 patients without electrical cardioversion experi-
enced a thromboembolic complication.
DISCUSSION
Main findings. This prospective, single-center, observa-
tional study evaluated the usefulness of TEE-guided car-
dioversion to prevent thromboembolic complications in
patients with AF and effective anticoagulation (INR 2 to 3)
at least three weeks before direct-current cardioversion.
During follow-up, there were no significant differences in
the rate of embolic events between the two treatment groups
(TTE vs. TEE). Overall, nine thromboembolic complica-
tions occurred. Six thromboembolic complications were
observed in the patients in whom the TEE-guided approach
to cardioversion was employed (6 [0.8%] of 719 patients),
compared with three thromboembolic complications in the
patients in whom the conventional approach was used (3
[0.8%] of 357 patients).
Severe hemorrhagic events occurred in two patients in theTa
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TEE group. No severe bleeding complications were ob-
served in the conventional treatment group.
Thromboembolism after cardioversion. In contrast to our
study, the objective of the recently published Assessment of
Cardioversion Using Transesophageal Echocardiography
(ACUTE) study (11) was to compare the conventional
anticoagulation strategy with the strategy of using TEE to
guide short-term anticoagulant therapy in patients with AF
and planned electrical cardioversion.
In the ACUTE study (11), there were no significant
differences in the rate of embolic events between the two
treatment groups (0.8% in the TEE-guided group vs. 0.5%
in the conventional group). The rate of embolic events was
comparable in both the ACUTE study (11) and present
study.
Patients in the TEE group were older and more often had
organic heart disease, impaired LV function, episodes of AF
lasting 48 h and a larger left atrium. However, all of these
differences are minor and not clinically relevant.
Transesophageal echocardiography in patients with ef-
fective anticoagulation. In the ACUTE study (11), a
thrombus was detected more often than in our study (13.8%
vs. 7.7%). This observation is explained by the different
anticoagulation strategy. Several investigators (22–24) have
reported resolution of thrombus in patients with AF after
more than two weeks of adjusted-dose warfarin therapy. In
the Stroke Prevention in Atrial Fibrillation (SPAF-III)
trial, thrombi were noted in 10% of all patients (22,23).
Thrombi were seen with a similar frequency in both
treatment groups (adjusted-dose warfarin [INR 2 to 3] and
combination therapy with low-dose warfarin therapy [INR
1.2 to 1.5] and aspirin), when TEE was performed within
two weeks of randomization, but the incidence in the
adjusted-dose warfarin group was much lower when TEE
was done later (22). Similarly, Collins et al. (24) reported
thrombus resolution in 86% of patients with AF after one
month of warfarin therapy (INR 2 to 3). In our study,
thrombus resolution was found in 55% of patients after one
month of adjusted-dose warfarin therapy (INR 3 to 3.5). A
similar prevalence of thrombi in the TEE-guided group
should be expected in the conventional treatment group.
These patients were not excluded from cardioversion, be-
cause they were not identified. Nevertheless, the embolic
rate was similar.
One might argue that in our study group, patients in the
conventional group differed from those in the TEE-guided
group. In contrast, when comparing the patient group in the
conventional arm of the ACUTE study with our patients in
the TEE-guided group, no major differences were observed.
This supports the hypothesis that the prevalence of thrombi
is 7.7% in patients after at least three weeks of effective
anticoagulation. Thromboembolism after cardioversion of
AF has been attributed to the dislodgment of preformed
atrial mural thrombi during the resumption of atrial con-
traction (8,25,26). However, our observation suggests that
thromboembolism after cardioversion may more often arise
as a consequence of the effects of cardioversion than from
the dislodgment of a pre-existent thrombi.
Our understanding is that the recommendation of three
weeks of anticoagulation before cardioversion is empirical,
and there is no such study to prove that three weeks of
anticoagulation is necessary. Investigators in this field may
wish to study whether a shorter period of anticoagulation
and cardioversion without TEE still provides a similar rate
of embolic events. It is possible that the reason we do not
have a significant difference in the embolic rate between
cardioversion with and without TEE is that the duration of
anticoagulation before cardioversion may not make much
difference clinically, although this will be difficult to prove.
Severe bleeding complications. In the ACUTE study
(11), the rate of hemorrhagic events was significantly lower
in the TEE-group than in the conventional group (2.9% vs.
5.5%). A comparison of severe hemorrhagic events showed
no significant differences. In the present study, hemorrhagic
events occurred in two patients in the TEE group. No
bleeding complications were observed in the conventional
treatment group. In both patients with bleeding complica-
tions, the INR was 3.
Study limitations. This study was not randomized; it is a
clinical, observational study from a single center. The study
included a control period with conventional cardioversion
and a TEE-guided approach. Patients who had the TEE-
guided approach to direct-current cardioversion were sicker
in terms of more often having structural heart disease, LV
dysfunction and a larger left atrium. However, these differ-
ences are minor and not clinically relevant. Furthermore, the
low prevalence of thromboembolic events limits the conclu-
sions that can be drawn from our data.
Conclusions. The results of this study, in combination
with the results of the ACUTE study, may have two clinical
implications: 1) TEE before direct-current cardioversion is
not needed in patients with effective anticoagulation at least
three weeks before cardioversion; and 2) if TEE is per-
formed early, more thrombi will be detected and more
patients will be excluded from cardioversion. However, in
patients with a normal TEE study, early cardioversion can
be performed safely. The impact of thrombi detected during
TEE on long-term prognosis must be evaluated.
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